Literature DB >> 11560757

Unusual evolution of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.

B Brichard1, F Smets, E Sokal, P Clapuyt, C Vermylen, G Cornu, J Rahier, J B Otte.   

Abstract

We report the case of a child who developed, 2 yr after orthotopic liver transplantation (OLTx) for biliary atresia, a multi-focal hepatic tumor with lymphonodular metastases, identified as an Epstein-Barr virus (EBV)-associated leiomyosarcoma. Chemotherapy was given without tumor response. Subsequently, slow growth of the tumor was observed. Immunosuppression was tapered and stopped 9 yr after transplantation. At the present time, 12 yr after the discovery of the first hepatic lesions, the patient is alive and completely symptom-free, the abdominal masses are stable, and liver function tests are completely normal. Smooth muscle tumors are increasingly recognized in children with various immunodeficiencies occurring after organ transplantation. This unusual evolution of a clinically aggressive tumor into a stable disease after restoration of immunity confirms that the immune status of the patient is a crucial factor.

Entities:  

Mesh:

Year:  2001        PMID: 11560757     DOI: 10.1034/j.1399-3046.2001.00022.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  22 in total

1.  An appendiceal leiomyoma in a child with acquired immunodeficiency syndrome.

Authors:  Elliot Sambol; Danielle Patterson; Rafael Rivera; Dariusz Borys; M Alba Greco; Aditya Kaul; Evan P Nadler
Journal:  Pediatr Surg Int       Date:  2006-08-30       Impact factor: 1.827

Review 2.  Primary hepatic leiomyosarcoma--a rare neoplasm in an adult patient with AIDS: second case report and literature review.

Authors:  Humberto Metta; Marcelo Corti; Norberto Trione; Daniela Masini; Jorge Monestes; Mariana Rizzolo; Marcela Carballido
Journal:  J Gastrointest Cancer       Date:  2014-12

3.  Primary hepatic leiomyosarcoma in a patient with autosomal dominant polycystic kidney disease.

Authors:  Takashi Iida; Tamaki Maeda; Yoshifumi Amari; Takatomi Yurugi; Yoshitane Tsukamoto; Fumitaka Nakajima
Journal:  CEN Case Rep       Date:  2017-03-04

Review 4.  Unusually young age distribution of primary hepatic leiomyosarcoma: case series and review of the adult literature.

Authors:  Achraf Shamseddine; Walid Faraj; Deborah Mukherji; Nadim El Majzoub; Mohamed Khalife; Ayman Soubra; Ali Shamseddine
Journal:  World J Surg Oncol       Date:  2010-07-01       Impact factor: 2.754

5.  Liver transplantation for primary hepatic leiomyosarcoma: a case report and review of the literatures.

Authors:  Xiao Liang; Shi Xiao-Min; Xie Jiang-Ping; Yang Jie-Yu; Zhang Xiao-Jun; Fu Zhi-Ren; Ding Guo-Shan; Li Rui-Dong
Journal:  Med Oncol       Date:  2009-12-09       Impact factor: 3.064

6.  Primary hepatic leiomyosarcoma: Case report and literature review.

Authors:  Nairuthya Shivathirthan; Junji Kita; Yukihiro Iso; Hiroyuki Hachiya; Park Kyunghwa; Tokihiko Sawada; Keiichi Kubota
Journal:  World J Gastrointest Oncol       Date:  2011-10-15

7.  Imaging features of primary hepatic leiomyosarcoma: A case report and review of literature.

Authors:  Wei-Fu Lv; Jian-Kui Han; DE-Lei Cheng; Wen-Jing Tang; Dong Lu
Journal:  Oncol Lett       Date:  2015-03-03       Impact factor: 2.967

8.  Brain involvement in multicentric Epstein-Barr virus-associated smooth muscle tumours in a child after kidney transplantation.

Authors:  Sabah Boudjemaa; Françoise Boman; Vincent Guigonis; Liliane Boccon-Gibod
Journal:  Virchows Arch       Date:  2004-04       Impact factor: 4.064

9.  EBV-associated hepatic smooth muscle tumor of uncertain biologic behavior after heart transplantation in a pediatric patient: case report.

Authors:  Yan Liu; Suneetha Chintalapati; Robin Dietz; Adnan S Raza; Jun Wang; Anwar Sultana Raza
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 10.  Primary hepatic sarcomas: CT findings.

Authors:  Ri-Sheng Yu; Ying Chen; Biao Jiang; Liu-Hong Wang; Xiu-Fang Xu
Journal:  Eur Radiol       Date:  2008-05-08       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.